Close menu




October 14th, 2026 | 05:30 CEST

Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

  • Tungsten
  • Raw materials
  • Critical raw materials
  • Geopolitics
  • Defence industry
  • Armaments
  • Military
  • Supply chains
  • Investments
Photo credits: Pixabay

The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: Almonty Industries Inc | CA0203987072 , RHEINMETALL AG | DE0007030009 , DE0006305006

Almonty Industries: Cash Flow and Earnings Outlook Becomes Clearer

The first bags of tungsten concentrate from Sangdong have been produced and are scheduled for shipment at the end of the month. Just a few weeks later, the material can be booked as revenue. For Western industrial customers, this creates an additional, long-awaited source of supply outside China.

Almonty has been producing tungsten concentrate at its Panasqueira mine in Portugal for some time, and its US property is expected to follow soon. However, the Sangdong mine in South Korea is clearly at the centre of the company’s expansion plans. The company’s position is set to strengthen further in the years ahead. Phase 2 of the expansion is intended to increase processing capacity to up to 1.2 million tonnes of ore annually from 2027.

Tungsten is used in tools, industrial components and military applications because of its hardness and temperature resistance and is virtually irreplaceable. On the sales side, a solid foundation is already in place. In July, Almonty extended its supply contract with Global Tungsten & Powders, a company in the Plansee Group, to 21 years from the first delivery. The agreement covers around 90% of Phase 1 production output.

Almonty also has an extremely strong financial position. At the end of June, cash and cash equivalents stood at around CAD 1.23 billion. The USD 800 million convertible senior notes offering placed in June, with a 2.25% coupon and a 2031 maturity, contributed a substantial share of this. The company has already used part of the funds to repay expensive loans and buy back shares. Acquisitions could also take place in the future. Analysts at DA Davidson set a price target of USD 33 for the stock, which is currently trading at around USD 11.

Rheinmetall: It Must Deliver

The group supplies armed forces with vehicles, ammunition, air defence and digital systems. Since acquiring Naval Vessels Lürssen, it has also included naval shipbuilding. However, this segment has so far fallen considerably short of expectations. In early October, the defence giant announced the start of satellite production in Neuss. In this area, as in others, Rheinmetall does not operate alone but through partnerships, meaning the company does not receive the full returns. Analysts are increasingly criticising this.

In the first half of the year, revenue grew by around 39% to EUR 5.227 billion. Operating profit rose 74% to EUR 786 million. Higher production volumes and a more favourable product mix improved profitability. However, procurement decisions remain a risk. Capacity expansion requires substantial funds. Cash flow from continuing operations was minus EUR 1.616 billion, with inventories and advance expenditure in particular tying up capital.

Net debt stood at around EUR 2.72 billion at the end of June. Following the cancellation of the F126 frigate programme, Rheinmetall had already had to reduce its revenue forecast for the current year by around EUR 300 million to EUR 13.7 to 14.2 billion, but firmly maintained its operating margin target of around 19%. Analysts nevertheless see attractive upside potential for the stock.

Deutz: Decisive Acquisition

Deutz sells engines, power supply solutions and services to machinery manufacturers and operators. The agreed acquisition of Flensburger Fahrzeugbau Gesellschaft (FFGT) is intended to significantly increase the group's defence business and overall profitability. FFG develops, modernises and maintains military vehicles. According to the company, completion of the transaction, worth around EUR 1.6 billion, is scheduled for the end of 2026, or Q1 2027 at the latest. Deutz expects FFG to generate more than EUR 1 billion in revenue next year, with an operating margin of over 20%.

In September, the company raised about EUR 179 million gross through a capital increase, increasing the number of shares by 10%. The fresh equity also improves the balance sheet ratios. The existing business grew in the first half of the year. Revenue grew 10.7% to EUR 1.115 billion, while adjusted operating profit rose to EUR 79.7 million. Free cash flow before acquisitions remained negative at minus EUR 29.7 million.

Analysts are bullish on the stock. The opportunity lies in a more profitable business mix and additional service revenue. This is counterbalanced by integration risks, higher financing costs and the engine business's dependence on the economic cycle.

Conclusion

With the imminent shipment of the first tungsten concentrate from Sangdong, a clearer picture of cash flows and earnings for the coming year can soon emerge. Production is expected to increase significantly over the medium term through a second expansion phase and the start of production in the US. Analysts see substantial upside potential for Almonty's stock. Rheinmetall has a broad industrial base, but faces high growth expectations, significant capital requirements and the need to deliver on its commitments. Deutz is pursuing an interesting growth opportunity through its acquisition of FFG.


Conflict of interest

Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

For this reason, there is a concrete conflict of interest.

The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

Risk notice

Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


Der Autor

Carsten Mainitz

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author



Related comments:

Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

  • Biosimilar
  • FDA
  • Milestone
  • Cancer therapy
  • Pharma
  • Patents
  • Investments

When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

Read

Commented by Tarik Dede on October 13th, 2026 | 05:31 CEST

Speculative Stocks in Focus: Opportunities in Super Micro Computer, Strategic Resources and Infineon

  • Infineon
  • Strategic Resources
  • Super Micro Computer
  • Speculation
  • Geopolitics
  • AI

In recent days and weeks, rising global bond yields have not been the only source of considerable uncertainty in equity markets. Instead, the massive financing needs of tech companies are becoming increasingly apparent. SpaceX plans to raise USD 40 billion through borrowing, while Oracle and OpenAI also appear to need more money. Not least, media reports say Japan's SoftBank is trying to raise up to USD 100 billion from investors in the Middle East for its AI plans. Added to this is a very high level of concentration in the major US indices. The three largest stocks, Nvidia, Apple and Microsoft, now account for 21% of the S&P 500. Based on Q3 estimates, more than two-thirds of earnings growth in this index now comes from the AI sector. The rest of the US economy is not really performing. In such volatile periods, it is worth looking at speculative stocks. These often move disproportionately following sharp market movements and offer leverage on the respective sector. Today, we take a look at the shares of Super Micro Computer, Strategic Resources and Infineon.

Read

Commented by Armin Schulz on October 13th, 2026 | 05:26 CEST

Almonty Industries, Rheinmetall, Lockheed Martin – Tungsten, Defence and a Share Price Decline That Could Open Up Opportunities

  • Almonty Industries
  • Rheinmetall
  • Lockheed Martin
  • Tungsten
  • Tungsten Mine
  • Tungsten Concentrate
  • Sangdong
  • Defence
  • Defence Industry

Sangdong is producing tungsten again for the first time since 1993. Almonty's South Korean mine is now supplying a raw material from outside China that is urgently needed in defence and is also found in an increasing number of high-tech devices. China's export restrictions have driven up tungsten prices in the West, while demand remains strong. The same is true of defence. On September 14, Rheinmetall booked an order for tens of thousands of artillery shells, while Lockheed Martin announced a framework agreement worth up to USD 1.2 billion for tactical missiles on September 21. Yet the stock market has so far shown little reaction to these developments. All three stocks are under pressure. We therefore take a closer look at Almonty Industries, Rheinmetall and Lockheed Martin.

Read